Abstracts tagged "Biologics"

Abstract Number: 1914 • 2013 ACR/ARHP Annual Meeting
Patient and Physician Perspectives On Family Planning and Pregnancy Issues In Systemic Inflammatory Diseases: Mind The Gap!
Megan E. B. Clowse¹, Eliza Chakravarty², Daphnee S. Pushparajah³, Sarah Mertens³ and Caroline Gordon⁴, ¹Duke University Medical Center, Durham, NC, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³UCB Pharma, Brussels, Belgium, ⁴School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Autoimmune and inflammatory diseases often affect women of reproductive age and can impact pregnancy outcomes. This patient (pt) group has important concerns about family…
Abstract Number: 1365 • 2013 ACR/ARHP Annual Meeting
Incidence Of Hepatitis B Virus Reactivation In Patients With Rheumatoid Arthritis During Treatment With Biologics
Jun Nakamura¹, Takao Nagashima¹, Katsuya Nagatani², Taku Yoshio³, Masahiro Iwamoto⁴ and Seiji Minota⁵, ¹Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ²Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ³Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, ⁴Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Tochigi, Japan, ⁵The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan
Background/Purpose: Reactivation of hepatitis B virus (HBV) is very problematic in patients who are receiving biologics. Optimal precaution and management for those patients are still…
Abstract Number: 446 • 2013 ACR/ARHP Annual Meeting
Remission Rates During Golimumab Treatment For Rheumatoid Arthritis Are Associated With Differences In Baseline Disease States Across Geographic Regions
P Durez¹, K Pavelka², M Lazaro³, A Garcia Kutzbach⁴, R Moots⁵, H Amital⁶, R Yao⁷, M Govoni^8,9, N Vastesaeger¹⁰ and HH Weng⁷, ¹Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Revmatologicky Ustav, Praha, Czech Republic, ³IARI Instituto de Asistencia Reumatologica Integral, Buenos Aires, Argentina, ⁴AGAR Francisco Marroquin University, Guatemala City, Guatemala, ⁵University Hospital Aintree, Liverpool, United Kingdom, ⁶Sheba Medical Center, Tel-Hashomer, Israel, ⁷Merck & Co., Inc., Whitehouse Station, NJ, ⁸MSD Italy, Rome, Italy, ⁹Merck Sharp & Dohme, Rome, Italy, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Regional differences in practice patterns and access to biologic treatment for rheumatoid arthritis (RA) may lead to regional differences in baseline disease characteristics, which…
Abstract Number: 2680 • 2013 ACR/ARHP Annual Meeting
Risk of Subsequent Infection among Rheumatoid Arthritis Patients Using Biologics
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸, Paul M. Muntner¹ and Jeffrey R. Curtis³, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Much has been written about infections associated with biologic agents in patients with rheumatoid arthritis (RA). However, less is known about the risk of…
Abstract Number: 1790 • 2013 ACR/ARHP Annual Meeting
Serum Amyloid A Levels Model Rheumatoid Arthritis Disease Activity Better Than C-Reactive Protein Levels Especially During Treatment With Anti-Tumor Necrosis Factor α Therapy (Etanercept)
Ilinca D. Metes¹, Douglas W. Chew², Aarat M. Patel¹, G.K. Balasubramani³, Jeffrey R. Curtis⁴, S. Louis Bridges Jr.⁵, Stephen R. Wisniewski⁶, Larry W. Moreland⁷ and Marc C. Levesque⁸, ¹Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁷Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: C reactive protein (CRP) levels have been used extensively to model disease activity in rheumatoid arthritis (RA). However, TNF antagonist therapy (and likely therapy…
Abstract Number: 1140 • 2013 ACR/ARHP Annual Meeting
Study Of The Antibody Titer By Influenza Vaccination In Rheumatoid Arthritis Patients Treated With Biologics In JAPAN
Hisato Ishikawa¹, Daihei Kida², Yosuke Hattori³, Atsushi Kaneko³ and Tomotaro Sato⁴, ¹Nagoya Medical Center, nagano, Japan, ²Department of Rheumatology and Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁴Orthopaedic Surgery and Rheumatology, Nagoya Medical Center, National Hospital Organization, Nagoya, Japan
Background/Purpose: Vaccination for influenza virus is recommended for patients with rheumatoid arthritis (RA) with underlying such as disease elderly people over the age of 65,…
Abstract Number: 426 • 2013 ACR/ARHP Annual Meeting
Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
Paul Emery¹, Annette Szumski², Jack Bukowski³, Eustratios Bananis² and Lisa Marshall⁴, ¹Institute Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, ²Specialty Care, Pfizer Inc., Collegeville, PA, ³Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc., Collegeville, PA
Background/Purpose: Although frequently effective, treatment with synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) does not adequately control disease activity in all patients. Prompt identification of…
Abstract Number: 2373 • 2013 ACR/ARHP Annual Meeting
UK Clinical Practice Use Of Biologics In Monotherapy For The Treatment Of Patients With Rheumatoid Arthritis
Andrew J. Ostor¹, G. Chelliah², Theodoros Dimitroulas³, Margaret-Mary Gordon⁴, Nicola Hewson⁵, JA Mitchell⁵, Senam Beckley-Kartey⁶, Hok Pang⁶ and Jose Saraiva-Ribeiro⁶, ¹Department of Rheumatology, Addenbrookes Hospital, Cambridge, United Kingdom, ²Clinical Trials Unit, Wrightington Hospital, Wigan, United Kingdom, ³Department of Rheumatology, Research and Development, Dudley Group NHS Foundation Trust, Russell’s Hall Hospital, Dudley, United Kingdom, ⁴Rheumatology Department, Gartnavel General Hospital, Glasgow, United Kingdom, ⁵Syne Qua Non Ltd., Diss, United Kingdom, ⁶Medical Department, Roche, Welwyn Garden City, United Kingdom
Background/Purpose: NICE guidelines recommend that patients with severe active rheumatoid arthritis (RA) be treated with a biologic disease‑modifying anti‑rheumatic drug as monotherapy (bDMARD mono) if…
Abstract Number: 1800 • 2013 ACR/ARHP Annual Meeting
Persistent Fatty Lesions In The Vertebrae In Ankylosing Spondylitis Favor Subsequent New Syndesmophytes: Imaging Results Of a Phase III, Randomized, Placebo-Controlled Study
Kay-Geert A. Hermann¹, Xenofon Baraliakos², Jürgen Braun³, Stephen Xu⁴ and Benjamin Hsu⁴, ¹Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ²Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: In ankylosing spondylitis (AS), it is hypothesized that stepwise pathologic changes in the spine begin with active inflammation, then fatty degeneration (Fat), leading to…
Abstract Number: 1050 • 2013 ACR/ARHP Annual Meeting
Population-Based Analysis Of Treatment Patterns For Recently Diagnosed Rheumatoid Arthritis Patients In The United States
Martin M. Crane¹, Boyka Stoykova², Julie Priest¹, Nasha Wang¹, Henry Krzywy¹ and Rahul Ganguly³, ¹WW Epidemiology, GlaxoSmithKline, Durham, NC, ²Global Health Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom, ³Global Health Outcomes, GlaxoSmithKline, Durham, NC
Background/Purpose: As treatment paradigms for rheumatoid arthritis (RA) continue to evolve, population-based studies can help assess which strategies are being used in “real-world” practice for…
Abstract Number: 434 • 2013 ACR/ARHP Annual Meeting
Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study
Mark C. Genovese¹, Hilde Carlier², Janelle Erickson², Daniel Braun² and Subhashis Banerjee², ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Eli Lilly & Company, Indianapolis, IN
Background/Purpose: Ixekizumab, a monoclonal antibody that neutralizes IL-17A with high affinity and specificity, has been evaluated in patients (pts) with moderate to severe rheumatoid arthritis…
Abstract Number: 2383 • 2013 ACR/ARHP Annual Meeting
A Useful Mathematical Model Able To Predict The Early Response To Tocilizumab In Rheumatoid Arthritis
Chiara Stagnaro¹, Claudia Ferrari², Rosaria Talarico³, Camillo Giacomelli¹, Stefano Bombardieri¹ and Laura Bazzichi¹, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, Pisa, Italy
Background/Purpose: In the last few year the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…
Abstract Number: 1736 • 2013 ACR/ARHP Annual Meeting
A Randomized, Controlled, Multicenter, 2‑Arm, Parallel‑Group, Double-Blind Study To Demonstrate The Equivalence Of CT-P10 To Innovator Rituximab With Respect To Pharmacokinetic Profile In Patients With Rheumatoid Arthritis
Dae-Hyun Yoo¹, Won Park², Slawomir Jeka³, Fidencio Cons Molina⁴, Pawel Hrycaj⁵, Piotr Wiland⁶, Wolfgang Spieler⁷, Jan Brzezicki⁸, Eun Young Lee⁹, Francisco G. Medina-Rodriguez¹⁰, Pavel Shesternya¹¹, Sebastiao Radominski¹², Marina Stanislav¹³, Volodymyr Kovalenko¹⁴, Dong Hyuk Sheen¹⁵, Mie Jin Lim¹⁶, Jung-Yoon Choe¹⁷, Sung Young Lee¹⁸, Seung-Cheol Shim¹⁹ and Chang-Hee Suh²⁰, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, ⁴Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁵Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁶Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁷Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁸Wojewodzki Szpital Zespolony Oddzial Reumatologiczny, Elblag, Poland, ⁹Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ¹⁰Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, ¹¹Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹²CETI Centro de Estudos em Terapias Inovadoras Ltda, Curitiba, Brazil, ¹³Central Russian National Institute of Rheumatology, Russian Academy of Medical Science, Moscow, Russia, ¹⁴Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁵Rheumatology, Eulji University Hospital, DaeJeon, South Korea, ¹⁶Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ¹⁷Rheumatology, Daegu Catholic University Medical Center, Daegu, South Korea, ¹⁸Clinical Planning and Medical Affairs Department, CELLTRION, Inc., Incheon, South Korea, ¹⁹Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ²⁰Department of Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose: CT-P10 was developed as a biosimilar candidate to innovator rituximab (RTX), an anti-CD20 monoclonal antibody. This trial is a phase I study to demonstrate…
Abstract Number: 1022 • 2013 ACR/ARHP Annual Meeting
Initiation Of Biologic Therapy: The Patient Perspective
Amir Goren¹, Susan C. Bolge², Duncan Brown³, Roxanne Meyer⁴ and Seth Ginsberg⁵, ¹Kantar Health, New York, NY, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Kantar Health, New york, NY, ⁴Janssen Scientific Affairs, LLC, Horsham, NY, ⁵Creaky Joints, New York, NY
Background/Purpose: Current guidelines for the treatment of rheumatoid arthritis (RA) recommend that patients who are not adequately responding to treatment with disease modifying anti-rheumatic drugs…
Abstract Number: 363 • 2013 ACR/ARHP Annual Meeting
Comparing Myocardial Infarction Risks Associated With Biologics Of Varying Mechanisms Of Action Among Older RA Patients
Jeffrey R. Curtis¹, Huifeng Yun², Jie Zhang³, Fenglong Xie⁴, Lang Chen⁵, Emily Levitan², James Lewis⁶, Timothy Beukelman⁷, Kenneth G. Saag⁸ and Iris Navarro-Millan⁵, ¹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ²Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Pennsylvania, Philadelphia, PA, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Anti-TNF biologics have been associated with a reduced risk for acute myocardial infarction (AMI) in some rheumatoid arthritis (RA) populations. The comparative risks for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].